- Home
- IGMS vs NCSM Comparison
IGMS vs NCSM Comparison
Compare IGMS & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- NCSM
- Stock Information
- Founded
- IGMS 1993
- NCSM 2006
- Country
- IGMS United States
- NCSM United States
- Employees
- IGMS N/A
- NCSM N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- IGMS Health Care
- NCSM Energy
- Exchange
- IGMS Nasdaq
- NCSM Nasdaq
- Market Cap
- IGMS 82.1M
- NCSM 79.3M
- IPO Year
- IGMS 2019
- NCSM 2017
- Fundamental
- Price
- IGMS $1.17
- NCSM $32.32
- Analyst Decision
- IGMS Hold
- NCSM
- Analyst Count
- IGMS 8
- NCSM 0
- Target Price
- IGMS $6.00
- NCSM N/A
- AVG Volume (30 Days)
- IGMS 211.8K
- NCSM 6.9K
- Earning Date
- IGMS 08-13-2025
- NCSM 07-30-2025
- Dividend Yield
- IGMS N/A
- NCSM N/A
- EPS Growth
- IGMS N/A
- NCSM N/A
- EPS
- IGMS N/A
- NCSM 3.27
- Revenue
- IGMS $2,681,000.00
- NCSM $168,704,000.00
- Revenue This Year
- IGMS $134.30
- NCSM $7.17
- Revenue Next Year
- IGMS $22.37
- NCSM $5.44
- P/E Ratio
- IGMS N/A
- NCSM $9.90
- Revenue Growth
- IGMS 27.36
- NCSM 18.16
- 52 Week Low
- IGMS $0.92
- NCSM $15.90
- 52 Week High
- IGMS $22.50
- NCSM $38.95
- Technical
- Relative Strength Index (RSI)
- IGMS 42.70
- NCSM 58.18
- Support Level
- IGMS $1.17
- NCSM $30.56
- Resistance Level
- IGMS $1.40
- NCSM $32.18
- Average True Range (ATR)
- IGMS 0.07
- NCSM 1.06
- MACD
- IGMS -0.01
- NCSM 0.24
- Stochastic Oscillator
- IGMS 4.17
- NCSM 97.35
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.